Literature DB >> 7817982

Cytokines in Crohn's colitis.

M E Sher1, A J D'Angelo, T A Stein, B Bailey, G Burns, L Wise.   

Abstract

BACKGROUND: Increasing evidence points to a pathologic role for cytokines in Crohn's colitis. Levels of cytokines are increased in diseased segments of colon in Crohn's colitis, but no one has studied the concentration of cytokines in clinically and histologically nondiseased segments.
METHODS: Mucosal biopsies were obtained from 7 patients with active segmental Crohn's colitis and from 7 controls without inflammatory bowel disease. The concentration of Interleukin (IL)-1 beta, IL-2, IL-6, and IL-8 in patients and controls were determined using enzyme linked immunosorbent assay and compared. Histologic sections were also performed to confirm diseased and nondiseased segments of colon.
RESULTS: The concentrations of IL-1 beta, IL-6, and IL-8 were significantly higher in the involved segments of colon (10.3 +/- 4.1, 3.7 +/- 1.0, 34.4 +/- 6.9 picograms [pg] per mg) when compared to controls (1.8 +/- 0.5, 1.1 +/- 0.5, 5.3 +/- 1.0 pg/mg). The concentrations of IL-1 beta, IL-2, and IL-8 (8.5 +/- 2.9, 5.3 +/- 1.2, 26.3 +/- 8.8 pg/mg) in normal appearing segments of colon of patients with Crohn's colitis were also significantly higher than in controls, whose IL-2 level was 2.0 +/- 0.5 pg/mg. IL-1 beta and IL-8 were significantly more concentrated in both the involved and uninvolved colonic segments of patients with Crohn's colitis compared to controls. IL-2 and IL-6 were also more concentrated in Crohn's patients than in controls, but not significantly. The differences in interleukin concentrations between involved and uninvolved segments of colon in patients with segmental Crohn's colitis were not significant.
CONCLUSIONS: Although Crohn's colitis is often a segmental disease, concentrations of IL-1 beta and IL-8 are increased throughout the entire colon. These observations reinforce the hypothesis that Crohn's colitis involves the whole colon even when this is not apparent clinically or histologically.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7817982     DOI: 10.1016/s0002-9610(99)80121-4

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  12 in total

1.  Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation.

Authors:  I B Autenrieth; N Bucheler; E Bohn; G Heinze; I Horak
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

2.  In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

Authors:  J M Reimund; S Dumont; C D Muller; J S Kenney; M Kedinger; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

3.  Jejunal brush border microvillous alterations in Giardia muris-infected mice: role of T lymphocytes and interleukin-6.

Authors:  K G Scott; M R Logan; G M Klammer; D A Teoh; A G Buret
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

Authors:  J M Reimund; C Wittersheim; S Dumont; C D Muller; J S Kenney; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

5.  Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.

Authors:  S Nikolaus; P Rutgeerts; R Fedorak; A H Steinhart; G E Wild; D Theuer; J Möhrle; S Schreiber
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

6.  Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1.

Authors:  Catherine M Cahill; Jack T Rogers
Journal:  J Biol Chem       Date:  2008-05-30       Impact factor: 5.157

7.  Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release.

Authors:  K Gronert; A Gewirtz; J L Madara; C N Serhan
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  Cytokines in inflammatory bowel disease.

Authors:  P L Beck; J L Wallace
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

9.  The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation.

Authors:  W E Longo; L J Damore; J E Mazuski; G S Smith; N Panesar; D L Kaminski
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

10.  Human intestinal epithelial and smooth muscle cells are potent producers of IL-6.

Authors:  Edmond K Ng; Ninder Panesar; Walter E Longo; Marc J Shapiro; Donald L Kaminski; Kym C Tolman; John E Mazuski
Journal:  Mediators Inflamm       Date:  2003-02       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.